肿瘤细胞治疗研究
ALL SOURCES
A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasma
CD123 靶向 CAR-T 细胞疗法在 r/r AML 和 BPDCN 患者中是可行的，并显示出良好的安全性特征，包括既往接受过 alloHCT 的患者。尽管估计的总体完全缓解率不高，但这些发现为进一步优化 CD123 CAR-T 细胞设计、患者选择和联合策略提供了基础。
Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.
Honing CAR T cells to tackle acute myeloid leukemia.
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.
Cytokine-mediated CAR T therapy resistance in AML.
Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity.
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia.
Blastic Plasmacytoid Dendritic Cell Neoplasm.
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia.
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
